Bharat Biotech, based in Hyderabad, has submitted a phase 3 clinical trial application to the Drugs Controller General of India (DCGI) for booster doses of their intranasal Covid-19 vaccine, which can be administered to persons who have already had Covaxin and Covishield vaccines, according to sources.
